Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SYN608, a Poly ADP-ribose Glycohydrolase (PARG) Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

NCT07088588 is registered in ClinicalTrials.gov with Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd as lead sponsor.

NCT NCT07088588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07088588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SYN608, a Poly ADP-ribose Glycohydrolase (PARG) Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 31, 2025
Completion date
October 31, 2028
Enrollment
105 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid cancer, brca mutation, breast cancer, hrr deficiency, metastatic solid tumor, ovarian cancer